J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
First published on September 29, 2009
The Journal of Clinical Pharmacology 2009, doi:10.1177/0091270009349378
This Article
Right arrow Full Text (JCP OnlineFirst[PDF])
Right arrow Supplementary Tables
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Google Scholar
Right arrow Articles by Brown, K. S.
Right arrow Articles by Salazar, D. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, K. S.
Right arrow Articles by Salazar, D. E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
©© 2009 American College of Clinical Pharmacology, Inc.
The Journal of Clinical Pharmacology, 10.1177/0091270009349378

Article

Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide

Karen S. Brown 1*, Ingrid C. Armstrong 1, Antonia Wang 1, Joseph R. Walker 1, Robert J. Noveck 2, Dennis Swearingen 3, Mark Allison 3, James C. Kissling 3, James Kisicki 3, and Daniel E. Salazar 1

1 Daiichi Sankyo Pharma Development
2 Duke University School of Medicine
3 MDS Pharma Services

* To whom correspondence should be addressed. E-mail: kbrown{at}dsus.com.


  Abstract
The purpose of this study was to assess effects of colesevelam on the pharmacokinetics of glyburide, levothyroxine, estrogen estradiol (EE), norethindrone (NET), pioglitazone, and repaglinide in healthy volunteers. Six drugs with a potential to interact with colesevelam were studied in open-label, randomized clinical studies. The presence of a drug interaction was concluded if the 90% confidence intervals for the geometric least squares mean ratios of AUC0-t (AUC0-48 for levothyroxine) and Cmax fell outside the no-effect limits of (80.0%, 125.0%). Concomitant administration of colesevelam had no effect on the AUC0-t or Cmax of pioglitazone but significantly decreased the AUC0-t and Cmax of glyburide, levothyroxine, and EE and the Cmax of repaglinide and NET. AUC0-t and of glyburide and EE, but not repaglinide or NET, were Cmax significantly decreased when the drug was given 1 hour before colesevelam. When glyburide, EE, or levothyroxine was given 4 hours before colesevelam, no drug interaction was observed. Although colesevelam has a cleaner drug interaction profile than other bile acid sequestrants, it does interfere with absorption of some drugs. A 4-hour window appears sufficient to eliminate these interactions.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the American College of Clinical Pharmacology